In order to test the function of ERO1α in pancreatic cancer cells, we used a CRISPR/Cas9 approach to delete the corresponding gene and assessed the impact on oncogenic potential in a range of different assays. This evidence concerns the gene ERO1A and familial pancreatic carcinoma.